文献速递胸部肿瘤

可切除III期NSCLC十年总生存:ESPATUE随机试验长期生存与竞争风险分析

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.
PubMed 文献 · Eur J Cancer · 2026-02-04

ESPATUE试验纳入246例医学和功能可手术的III期NSCLC患者,诱导化疗后161例可切除者随机接受放化疗加强(A组80例)或确定性手术(B组81例)。竞争风险分析未显示任一局部治疗方式的优势,合并症死亡和第二肺癌死亡仍是长期风险。

要点

  • 可切除III期NSCLC诱导化疗后手术与放化疗加强的10年OS率分别为29.9%和28.3%,无显著差异。
  • 竞争风险分析未显示手术或放化疗加强在长期死亡风险上有任何偏好。
  • 合并症死亡和第二肺癌死亡是长期生存者的相关风险。

核心结论

  • 可切除III期NSCLC患者诱导化疗后接受手术或放化疗加强,10年总生存无显著差异。
  • 竞争风险分析未显示任一局部治疗方式在长期死亡风险上有相关偏好。
  • 合并症死亡和第二肺癌死亡仍是长期随访中的重要风险。

研究设计与样本

  • 随机对照试验ESPATUE,2004年1月至2013年1月纳入246例医学和功能可手术的III期NSCLC患者。
  • 诱导化疗后161例认为可切除者随机分为放化疗加强组(A组,n=80)和确定性手术组(B组,n=81)。
  • 诱导化疗为每21天重复3周期,顺铂50 mg/m2第1、8天,紫杉醇175 mg/m2第1天。
  • 同步放化疗为45 Gy,1.5 Gy每日两次,同步顺铂50 mg/m2第2、9天,长春瑞滨20 mg/m2第2、9天。
  • 对2022年2月仍存活患者更新总生存,中位随机至末次评估时间145.1个月(四分位距121.5-197.8)。

主要发现

  • 两组10年总生存比较P=0.70(log rank)。
  • 无进展生存、第二原发肺癌死亡、第一肺癌死亡、治疗相关死亡、非肺癌第二癌症死亡在两组间相当。

临床怎么用

  • 对于可切除III期NSCLC,诱导化疗后手术或放化疗加强均可作为局部治疗选择,长期生存无显著差异。
  • 长期随访中需关注合并症死亡和第二肺癌死亡风险。
  • 长期生存数据可作为正在进行的免疫治疗联合III期方案研究的基线参考。

局限性

  • 原文未报告竞争风险分析的具体数值和统计方法细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: More stage III non-small-cell lung cancer patients experience long-term survival (OS). ESPATUE-trial looked at surgery versus boost-radiochemotherapy following induction chemotherapy, consisting of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m2 on days 2 and 9, and concurrent vinorelbine 20 mg/m2 on days 2 and 9 (Eberhardt et al, J Clin Oncol 2015). Here, we update 10-years-OS and report competing-risks-of-deaths. METHODS: Complete trial design has been published. We updated OS for patients still alive at 2/2022. Patients were followed up on a yearly basis and showed up to get follow-up imaging and reevaluation. RESULTS: From 1/2004 until 1/2013 246 patients medically and functionally operable were enrolled. Following induction 161 considered resectable were randomized to radiochemotherapy-boost(arm 1/A;n = 80) or definitive surgery(arm 2/B;n = 81).The median time from randomization to last evaluation was 145.1 months(interquartile range 121.5-197.8). Patients in the arm that included surgery(B) had a 10-year overall survival rate of 29.9 %(20.2-40.3) and those with radiochemotherapy(A) a rate of 28.3 %(18.8-38.5; p = 0.70 log rank). Rates of progression-free survival, death from second priomary lung cancer, death from first lung cancer, treatment related death, death from second cancer without lung cancer were comparable in both study arms CONCLUSIONS: Long-term survival serves as baseline information for ongoing immunotherapy-based stage III protocols. No significant differences between local modalities radiochemotherapy and surgery were observed. A competing-risk-of-deaths-analysis showed no relevant preference for one arm. Death from comorbidities and death from second lung cancer remain relevant long-term-risks.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eberhardt WEE, Schulte C, Pöttgen C, et al. Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis. Eur J Cancer. 2026. PMID: 41702246. doi:10.1016/j.ejca.2026.116256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。